Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product …